Clinical Practice
Copyright ©2013 Baishideng Publishing Group Co.
World J Clin Cases. Nov 16, 2013; 1(8): 249-255
Published online Nov 16, 2013. doi: 10.12998/wjcc.v1.i8.249
Table 2 Distribution and bacteria isolated at control and test sites at baseline, 5 and 13 wk n (%)
Baseline
5 wk
13 wk
ControlTestControlTestControlTest
Actinomycesnaeslundii FG+veR3 (3.9)---1 (1.7)1 (1.6)
Actinomycesviscosus FG+veR2 (2.6)---1 (1.7)1 (1.6)
Bifidobacterium spp FG+veR4 (5.2)3 (7.1)2 (4)2 (3.6)1 (1.7)3 (4.9)
Clostridium spp FG+veR--7 (14)6 (11.3)--
Diphtheroid bacilli AG+veR2 (2.6)4 (9.5)2 (4)2 (3.6)3 (5.3)1 (1.6)
Escherichia coli FG-veR--1 (2)2 (3.6)--
Eubacterium spp FG+veR11 (1.3)--2 (3.6)--
Fusobacteriumnucleatum AnG-veR12 (2.6)-3 (6)4 (7.5)8 (14.2)-
Haemophilus spp FG-veR10 (13.1)3 (7.1)4 (8)2 (3.6)5 (8.9)3 (4.9)
Coagulase-negative Staphylococci FG+veC2 (2.6)2 (4.7)2 (4)1 (1.8)-4 (6.5)
Neisserria spp AG-veC8 (10.5)2 (4.7)2 (4)2 (3.6)1 (1.7)-
Peptostreptococcus AnG+veC5 (6.5)-----
Porphyromonasgingivalis AnG-veR1----2 (3.2)-
Prevotellaintermedia AnG-veR11 (1.3)1 (2.3)1 (2)1 (1.8)8 (14.2)-
Propionibacteriumgranulosum FG+veR-1 (2.3)----
Staphylococcus aureus FG+veC2 (2.6)1 (2.3)3 (6)7 (13.2)-2 (3.2)
Veillonellaparvula AnG-veC11 (1.3)1 (2.3)3 (6)1 (1.8)10 (17.8)1 (1.6)
Streptococci AG-veC25 (32.8)15 (35.7)15 (30)19 (35.8)11 (19.6)39 (63.9)
Campylobacter rectus FG-veR6 (7.8)4 (9.5)3 (6)-4 (7.1)2 (3.2)
Treponemadenticola AnG-veC11 (1.3)2 (4.7)1 (2)1 (1.8)--
Gemella spp FG+veC----2 (3.2)
Filifactoralocis FG+veR1 (1.3)3 (7.1)1 (2)1 (1.8)1 (1.7)2 (3.2)
Total (n)764250535661
P value0.5950.8950.0062